Barclays
ALT icon

Barclays’s Altimmune ALT Stock Holding History

Barclays’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$255K – 4836
2024
Q1 		$255K Buy
+25,000
New +$254K ﹤0.01% 3984

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's ALT Position: Q2 2026 in Review

Barclays increased its Altimmune (ALT) stake by 82% in Q2 2026, buying an estimated $474K and bringing the position to 351,587 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2751.

Barclays first reported a position in ALT in Q2 2013 and has held it in 31 quarters since. The position peaked at $12.5M in Q2 2022. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Barclays held 351,587 shares of Altimmune worth $1.07M as of Q2 2026.
  • Barclays bought 158,716 Altimmune shares in Q2 2026, an estimated $474K.
  • Altimmune made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2751 holding.
  • Barclays first reported a position in Altimmune in Q2 2013 and has held it in 31 quarters since.
  • Barclays's Altimmune position peaked at $12.5M in Q2 2022.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.